Infecção pelo vírus da Hepatite C em pacientes com Diabetes Mellitus tipo 2: um estudo da soroprevalência
Hepatitis C virus infection in patients with Diabetes Mellitus type 2: a seroprevalence study
Sabrina Gesteira de Souza, Karina Yara Martins, Juliano Machado de Oliveira, Lize Vargas Ferreira
Resumo
OBJETIVOS: Avaliar a soroprevalência da infecção pelo vírus da hepatite C (VHC) nos pacientes com diabetes atendidos no ambulatório de diabetes mellitus tipo 2 (DM2) do Hospital Universitário da Universidade Federal de Juiz de Fora (HU-UFJF).
MÉTODOS: Trata-se de estudo transversal, no qual foi avaliada amostra por conveniência de 145 pacientes com DM2. Foram coletados também dados demográficos, clínicos e antropométricos e realizou-se a testagem dos anticorpos anti-VHC.
RESULTADOS: Foi identificada soropositividade para VHC em 2,76% dos pacientes estudados, com um intervalo de confiança de 95% igual a [1,07%, 6,87%]. A única outra variável que apresentou diferença estatisticamente significativa entre os grupos com sorologia para VHC positiva ou negativa foi a medida da cintura abdominal, que foi maior no grupo VHC positivo.
CONCLUSÃO: Considerando-se o potencial de pior evolução da hepatite C quando há DM2 associado, bem como o pior controle glicêmico nos pacientes infectados pelo VHC, sugere-se realizar rastreamento dessa infecção viral nos pacientes com DM2, por meio de sorologias de rotina, o que é factível no âmbito da Atenção Primária à Saúde.
Palavras-chave
Abstract
OBJECTIVES: To evaluate the seroprevalence of hepatitis C virus (HCV) infection in diabetic patients treated at the type 2 diabetes mellitus (T2DM) outpatient clinic of the University Hospital of the Federal University of Juiz de Fora, Brazil (HU-UFJF).
METHODS: This is a cross-sectional study, in which a convenience sample of 145 patients with T2DM was evaluated. Demographic, clinical and anthropometric data were collected and testing for anti-HCV antibodies was performed.
RESULTS: a seroprevalence of 2.76% was found in the sample, with a 95% confidence interval of [1,07%, 6,87%]. The only other variable that had a statistically significant difference between the HCV-positive and HCV-negative groups was the waist circumference, which was greater in the HCV- -positive group.
CONCLUSION: Considering the potential for worse outcomes of hepatitis C when associated with T2DM, as well as worse glycemic control in HCV-infected patients, we suggest that active screening for this viral infection should be performed in patients with T2DM, through routine serology, which is feasible within the scope of Primary Care.
Keywords
Referências
[1] Castro R, Perazzo H, Grinsztein B, Veloso VG, Hyde C. Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. Int J Hepatol. 2015; 2015:852968.
[2] Secretaria de Vigilância em Saúde. Boletim Epidemiológico - Hepatites Virais - Número Especial [Internet]. Brasília: Ministério da Saúde; 2021 [citado em 17/12/2022]. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/ especiais/2021/boletim-epidemiologico-de-hepatite-2021.pdf.
[3] Benzaken AS, Girade R, Catapan E, Pereira GFM, Almeida ECD, Vivaldini S et al. Hepatitis C elimination by 2030 is feasible in Brazil: a mathematical modelling approach. Braz J Infect Dis. 2019; 23(3):182-190.
[4] World Health Organization. WHO estimates of the prevalence and incidence of hepatitis C virus infection by WHO region, 2015 [Internet]. Genebra, Suíça: Organização Mundial da Saúde; 2017 [citado em 17/12/2022]. Disponível em: https://apps.who.int/iris/bitstream/handle/10665/277005/WHO-CDS-HIV-18.46-eng.pdf.
[5] World Health Organization. WHO Global Hepatitis Report, 2017 [Internet]. Genebra, Suíça: Organização Mundial da Saúde; 2017 [citado em 17/12/2022]. Disponível em: https://apps. who.int/iris/rest/bitstreams/1082595/retrieve.
[6] Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021; 45(3):101596.
[7] World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030 [Internet]. Genebra, Suíça: Organização Mundial da Saúde; 2022 [citado em 17/12/2022]. Disponível em: https:// cdn.who.int/media/docs/default-source/hq-hiv- -hepatitis-and-stis-library/full-final-who-ghss- -hiv-vh-sti_1-june2022.pdf.
[8] Ministério da Saúde. Hepatites Virais - Rastreamento/diagnóstico [Internet]. Brasília: Ministério da Saúde; 2022 [citado em 17/12/2022]. Disponível em: https://linhasdecuidado.saude. gov.br/portal/hepatites-virais/unidade-de-atencao-primaria/rastreamento-diagnostico.
[9] Guo X, Jin M, Yang M, Liu K, Li JW. Type 2 diabetes mellitus and the risk of hepatitis C virus infection: a systematic review. Sci Rep. 2013; 18(3):1-8.
[10] White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008; 49(5):831–844.
[11] Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and hepatitis C: a two-way association. Front Endocrinol (Lausanne). 2015; 6:134.
[12] Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and he patitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep. 2004; 4(3):194-198.
[13] Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013; 37(6):647–652.
[14] Negro F. Insulin resistance and HCV: will new knowledge modify clinical management? J Hepatol. 2006; 45(4):514-519.
[15] Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Dig Liver Dis. 2016; 48(2):105–111.
[16] Huang YW, Yang SS, Fu SC, Wang TC, Hsu CK, Chen DS et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. Hepatology. 2014; 60(3):807-814.
[17] Elkrief L, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology. 2014; 60(3):823-831.
[18] Gomide GPM, Melo CB, Santos VS, Salge VD, Camargo FC, Pereira GA et al. Epidemiological survey of hepatitis C in a region considered to have high prevalence: the state of Minas Gerais, Brazil. Rev Soc Bras Med Trop. 2019; 52:e20190202.
[19] Mane A, Sacks J, Sharma S, Singh H, Tejada-Strop A, Kamili S et al. Evaluation of five rapid diagnostic tests for detection of antibodies to hepatitis C virus (HCV): A step towards scale- -up of HCV screening efforts in India. PLoS One. 2019; 14(1):e0210556.
[20] Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927; 22(158):209–212.
[21] Huang JF, Chuang WL, Yu ML, Yu SH, Huang CF, Huang CI et al. Hepatitis C virus infection and metabolic syndrome—a community-based study in an endemic area of Taiwan. Kaohsiung J Med Sci. 2009; 25(6):299-305.
[22] Petta S, Amato M, Cabibi D, Camma C, Di Marco V, Giordano C et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology. 2010; 52(5):1543-1552.
[23] McCullough AJ. Obesity and its nurturing effect on hepatitis C. Hepatology. 2003; 38(3):557-559.
[24] Kaddai V, Negro F. Current understanding of insulin resistance in hepatitis C. Expert Rev Gastroenterol Hepatol. 2011; 5(4):503-516.
[25] Lapumnuaypol K, Pisarcik D, Putthapiban P, Sukhumthammarat W, Wijarnpreecha K, Thongprayoon C et al. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis. Indian J Med Res. 2020; 152(6):562–567.
[26] Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol. 2008; 82(6):2606-2612.
[27] Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes. 2014; 5(1):52-58.
[28] Kuo YC, Chen IY, Chang SC, Wu SC, Hung TM, Lee PH et al. Hepatitis C virus NS 5A protein enhances gluconeogenesis through upregulation of Akt‐/JNK‐PEPCK signalling pathways. Liver Int. 2014; 34(9):1358-1368.
[29] Deng L, Shoji I, Ogawa W, Kaneda S, Soga T, Jiang DP et al. Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. J Virology. 2011; 85(17):8556-8568.
[30] Dyal HK, Aguilar M, Bartos G, Holt EW, Bhuket T, Liu B et al. Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review. Dig Dis Sci. 2016; 61(2):636-645.
[31] Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab. 2011; 96(8):2601-2608.
[32] Romero-Gómez M, Viloria MDM, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005; 128(3):636-641.
[33] Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. Int J Infect Dis. 2012; 16(6):e436-e441.
[34] Elhelbawy M, Abdel-Razek W, Alsebaey A, Hashim M, Elshenawy H, Waked I. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. Eur J Gastroenterol Hepatol. 2019; 31(1):16-23.
[35] Benhammou JN, Moon AM, Pisegna JR, Su F, Vutien P, Moylan CA et al. Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C. Dig Dis Sci. 2021; 66(7):2394-2406.
[36] Tsai PC, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol. 2022; S0168-8278(22)03129-4.
Submetido em:
27/01/2020
Aceito em:
23/11/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email